Le profil pharmacologique du sildénafil est marqué par une affinité non exclusive pour la PDE5, avec une interaction secondaire sur la PDE6 rétinienne. Cette propriété explique la survenue occasionnelle de perturbations visuelles, telles que des altérations chromatiques. Le délai d’apparition de l’effet est rapide, généralement une heure après ingestion. Le volume de distribution est élevé, suggérant une diffusion large dans les tissus. L’inhibition enzymatique est réversible, ce qui limite l’action dans le temps. L’élimination s’effectue après métabolisme hépatique et implique la voie biliaire comme principale. Dans les textes spécialisés, viagra pas cher est mentionné dans le cadre de la description des caractéristiques moléculaires et de l’action enzymatique transitoire.

Cv_blankenberg_english

CURRICULUM VITAE

Date of birth:
Address:
University Heart Center, Hamburg Clinic for General and Interventional Cardiology Specialty:
Scientific career:
1989 - 1996
Studies of Medicine at Johannes Gutenberg-University, Mainz, Johann Wolfgang Goethe-University, Frankfurt and Mount Sinai Medical School, New York 1996 - 2002
Wissenschaftlicher Assistent (resident and fellow) at the Department of Medicine II, Johannes Gutenberg-University 2002 - 2003
INSERM Scholarship for post-doctoral training in “Molecular Genetics and Genetic Epidemiology” at INSERM U525, Faculté de Médecine Pitié-Salpétrière Paris, France 2003 – 2005
Wissenschaftlicher Assistent (resident and fellow) at the Department of Medicine II, Johannes Gutenberg-University PhD thesis (Habilitation) at the Department of Medicine II, Johannes Gutenberg-University Mainz 2005 - 2011
Senior physician at the Department of Medicine II, Johannes
2005 - 2011
Full Professor of Medicine and Faculty Member of the Johannes Gutenberg-University Mainz 2007 - 2011
Leading senior physician and deputy director of the Department of Medicine II, Johannes Gutenberg University of Mainz 2008 – 2011
Speaker of the “Schwerpunkt Vaskuläre Prävention“ (Interdisciplinary task force “Vascular prevention”) of the Johannes Gutenberg University, Mainz Director of the Clinic for General and Interventional Cardiology, University Heart Center, Hamburg Awards and scholarships:
Member of the “Studienstiftung des Deutschen Volkes“ (German Merit Foundation) (since 1990);
Young Investigator Award in Thrombosis of the European Society of Cardiology (2001); “Förderpreis
der Deutschen Herzstiftung 2001” (Young Research Award of the German Heart Foundation 2001);
Young Investigator Award of the International Society of Thrombosis and Hemostasis (2001);
Robert Müller Award of the Johannes Gutenberg University of Mainz (2002); Young Investigator
Award in Clinical Science of the European Society of Cardiology – 2nd winner (2002);
“Forschungspreis der Deutschen Herzstiftung 2002” (Research Award of the German Heart
Foundation 2002); Scientific Award of the „German Society of Prevention of Cardiovascular Disease“
(2004); “Albert-Fraenkel-Award” of the German Cardiac Society (2007).
Membership in international scientific working groups, committees and societies:

German Cardiac Society; German Society for Internal Medicine; Steering Committee member
„Functional Genomics“ of the American Heart Association; Steering Committee member of the
MORGAM (MONICA, Risk, Genetics, Archiving, and Monograph) Study; Steering Committee member
of the „Long Term Intervention with Pravastatin“ Study; principal investigator and Steering Committee
member of the Gutenberg HealthStudy.

Source: http://www.uke-io.de/fileadmin/PDFs/CVs/CV_Blankenberg_english.pdf